ekonominyheter

TranslateRSSMobil
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too

Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too

Fool.com 18/11 18:00

Thanks to Merck, Regeneron Pharmaceuticals and Esperion Therapeutics likely won't have to run outcomes studies on their cholesterol drugs.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status